# LDEBIO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ldebio

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.leidebio.com
- Total disclosed funding: $7.1M
- Latest round: Series B (May 21, 2021)
- Investors on record: 4

## About

Based in Guangzhou, China and established in 2013, LDEBIO is a biotechnology company which focuses on research and development of in vitro diagnostics, medical reagents, medical devices, etc. In August 2019, LDEBIO raised over RMB 50 million in series B funding from new investor Guangzhou Jinyuan Kuntong Equity Investment Management. The company has a post-doctoral innovation center, AIMDX full immunity research center in the United States and Guangzhou Reid Medical Laboratory Co., Ltd.
The company focuses on the "full immune" diagnostic system-a new generation of in vitro diagnostic technology, which enables more accurate diagnostic analysis of complex immune-mediated diseases. The company focuses on major immune-mediated diseases.
In the future, the company will build a marketing team, increase marketing investment, develop innovative products for full immunodiagnosis, and improve reagent production capacity.

## Funding rounds

- Series B, May 21, 2021 — Shandong High-tech Investment Corporation, Funway Capital
- Series B, Aug 19, 2019, $7.1M — Jinyuan Kuntong Equity Investment Management
- Series A, Jan 20, 2018 — Fortune Capital

## Investors

- Fortune Capital — Series A
- Jinyuan Kuntong Equity Investment Management (https://capitalatlas.ai/funds/jinyuan-kuntong-equity-investment-management) — Series B
- Shandong High-tech Investment Corporation (https://capitalatlas.ai/funds/shandong-high-tech-investment-corporation) — Series B
- Funway Capital (https://capitalatlas.ai/funds/funway-capital) — Series B